BC Week In Review | Aug 10, 2018
Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower list...
BC Week In Review | Aug 10, 2018
Company News

Ironwood ends gout drug deal with AZ

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol. Ironwood said franchise test markets of the drugs did not meet...
BC Extra | Aug 7, 2018
Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower list...
BC Extra | Aug 6, 2018
Company News

Ironwood ends gout drug deal with AZ

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol. Ironwood said franchise test markets of the drugs did not meet...
BC Week In Review | Jul 13, 2018
Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
BC Extra | Jun 29, 2018
Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
BioCentury | May 5, 2018
Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Aug 28, 2017
Clinical News

FDA approves Ironwood's Duzallo for gout

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone. The company expects to launch the...
BC Extra | Aug 21, 2017
Company News

FDA approves Ironwood's gout combo

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone. The company expects to launch the...
Items per page:
1 - 10 of 13